WASHINGTON — The Association for Accessible Medicines has commented on an announcement by the Department of Commerce beginning a Section 232 investigation into possible tariffs and other trade remedies with the goal of encouraging more domestic manufacturing of pharmaceuticals.
“AAM and the generics and biosimilars industry look forward to working with the Commerce Department and the White House to engage constructively on ways to incent more domestic investment in the medicines supply chain,” said John Murphy III, president and CEO of the Association for Accessible Medicines. “As we have said countless times: a resilient and reliable generic medicines supply chain is critical to patient health, U.S. healthcare and national security interests. Tariffs, however, will only amplify the problems that already exist in the U.S. market for affordable medicines.
“Without substantive regulatory and reimbursement changes to the U.S. market, tariffs will exacerbate current shortages that hinder patient access today. Instead, we urge the Administration to work with us on a suite of reforms that prioritize patients, national security, and ultimately will lead to more resilient and reliable access here in the U.S. As was the case in the previous Trump Administration, we also support exemptions and carve-outs from tariffs for essential and short-supply medicines as well as for the base ingredients in those medicines.”
AMM Tariffs Fact Sheet: https://accessiblemeds.org/wp-content/uploads/2025/02/AAM-tariff-actions-should-ensure-access-to-lower-cost-generic-and-biosimilar-medicines.pdf
AAM Release on February Tariffs: https://accessiblemeds.org/resources/press-releases/aam-comments-new-tariffs/
AAM 2025 Advocacy Priorities: https://accessiblemeds.org/wp-content/uploads/2025/02/AAM-Protect-and-Defend-Patient-Access-Generics-Biosimilars.pdf
2024 U.S. Generic & Biosimilar Medicines Savings Report: https://accessiblemeds.org/resources/blog/2024-savings-report
